Morbidity and mortality secondary to cardiovascular disease is the major health problem in obese patients. Obese patients are burdened with an array of metabolic dysfunctions associated with excess weight which drive the cardiovascular disease evident in this population. While this correlation is well-established, mechanistic links that could be exploited therapeutically are largely lacking. In preliminary studies for this proposal, we have made two major observations that shed significant new light on this issue. The first is that loss of metabolic control in skeletal muscle appears to be the key trigger for vascular injury in obesity. Correction of rapid glucose disposal by deletion of genes that limit insulin signaling or muscle growth appear to restore endothelial function in vitro and may underpin cardiovascular defects systemically. The second observation is the NADPH Oxidase 1 (Nox1) is a major culprit in vascular defects in obesity. Nox1 is overexpressed in large and small vessels from obese mice and appears driven by glucose excess, potentially via upregulation of galectin-3. In the current proposal, we will rigorously test these concepts in three aims. The firs aim will use state-of-the-art molecular techniques in vitro to determine the signaling mechanisms by which changes in the plasma milieu, specifically glucose, induce changes in Nox expression and superoxide production with specific emphasis on the role of galectin-3.
The second aim will generate novel Nox1 and Galectin-3 KO mice on a genetically obese background to test the hypothesis that these two oxidant pathways contribute to vascular dysfunction in vitro with a specific emphasis on determining whether improving metabolism by increasing muscle mass obviates pro oxidant pathways.
The third aim will pursue these concepts in vivo, testing whether increased muscle mass or blocking the Nox1/Galectin-3 signaling axis improves cardiovascular outcomes like blood pressure and vascular adaptions to hemodynamic stress. Taken together, these studies will provide new information on the mechanisms, mediators and physiologic impact of obesity-induced metabolic dysfunction. Successful completion of these aims may identify new targets to aid in the treatment of some the most pressing clinical outcomes of obesity.

Public Health Relevance

Cardiovascular disease is the greatest health threat in the obese population, in part due to the metabolic dysfunction that accompanies obesity. Studies proposed in the application identify three new therapeutic targets, myostatin, Nox1 and galectin-3, which may uncouple the deleterious relationship between obesity and cardiovascular disease by breaking the 'metabolic connection'. Completion of these experiments will not only potentially validate these new targets but also better clarify why obesity causes cardiovascular disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL124773-01A1
Application #
8911095
Study Section
Hypertension and Microcirculation Study Section (HM)
Program Officer
Maric-Bilkan, Christine
Project Start
2015-04-01
Project End
2019-01-31
Budget Start
2015-04-01
Budget End
2016-01-31
Support Year
1
Fiscal Year
2015
Total Cost
$552,011
Indirect Cost
$186,031
Name
Georgia Regents University
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Augusta
State
GA
Country
United States
Zip Code
30912
Butcher, Joshua T; Mintz, James D; Larion, Sebastian et al. (2018) Increased Muscle Mass Protects Against Hypertension and Renal Injury in Obesity. J Am Heart Assoc 7:e009358
Barman, Scott A; Chen, Feng; Li, Xueyi et al. (2018) Galectin-3 Promotes Vascular Remodeling and Contributes to Pulmonary Hypertension. Am J Respir Crit Care Med 197:1488-1492
Fulton, David J R; Li, Xueyi; Bordan, Zsuzsanna et al. (2017) Reactive Oxygen and Nitrogen Species in the Development of Pulmonary Hypertension. Antioxidants (Basel) 6:
Yiew, Nicole K H; Chatterjee, Tapan K; Tang, Yao Liang et al. (2017) A novel role for the Wnt inhibitor APCDD1 in adipocyte differentiation: Implications for diet-induced obesity. J Biol Chem 292:6312-6324
Thompson, Jennifer A; Larion, Sebastian; Mintz, James D et al. (2017) Genetic Deletion of NADPH Oxidase 1 Rescues Microvascular Function in Mice With Metabolic Disease. Circ Res 121:502-511
Butcher, Joshua T; Ali, M Irfan; Ma, Merry W et al. (2017) Effect of myostatin deletion on cardiac and microvascular function. Physiol Rep 5:
Li, Xueyi; Weintraub, Daniel S; Fulton, David J R (2017) Beyond Impressions: How Altered Shear Stress Connects Hypoxic Signaling to Endothelial Inflammation. Arterioscler Thromb Vasc Biol 37:1987-1989
Thompson, Jennifer A; D'Angelo, Gerard; Mintz, James D et al. (2016) Pressor recovery after acute stress is impaired in high fructose-fed Lean Zucker rats. Physiol Rep 4:
Pati, Paramita; Fulton, David J R; Bagi, Zsolt et al. (2016) Low-Salt Diet and Circadian Dysfunction Synergize to Induce Angiotensin II-Dependent Hypertension in Mice. Hypertension 67:661-8
Chen, Feng; Li, Xueyi; Aquadro, Emily et al. (2016) Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension. Free Radic Biol Med 99:167-178

Showing the most recent 10 out of 19 publications